Skip to content

Nano Nuclear Energy NNE Payments For Research And Development Expense

Payments For Research And Development Expense at other companies

ON Semiconductor logo
ON SemiconductorON
$144.3M-12.1%
Boston Scientific logo
Boston ScientificBSX
$516M+16.5%
Erasca, Inc. logo
Erasca, Inc.ERAS
$150M
Teradyne, Inc. logo
Teradyne, Inc.TER
$135.56M+14.7%
Alumis Inc. logo
Alumis Inc.ALMS
$3.35M-74.0%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$3.53B+9.4%

Other financials

Income statement

See full
Net income-$9.2M+56.9%
EPS (diluted)-$0.18+68.4%

Balance sheet

See full
Cash & equivalents$197.7M+66.7%
Total debt$2.6M-8.7%
Total equity$595.9M+351%
Total assets$603.9M+335%

Cash flow

See full
Operating cash flow-$5.3M-121%
CapEx$4.6M+994%
Free cash flow-$9.6M-276%

Valuation

See full
Market cap$1.21B-22.0%
Enterprise value$1.01B-29.3%

Returns & leverage

See full
Return on equity-8.6%-3.9pp
Debt / equity0.0×
Current ratio95.7×+68.5×

Where this comes from

Reported directly by Nano Nuclear Energy in its filing.

Tagged under the XBRL concept NNE:PaymentsForResearchAndDevelopmentExpense.

The official record: Nano Nuclear Energy’s 10-K, filed December 18, 2025, on SEC EDGAR. View the filing →

Ask your AI about Nano Nuclear Energy's payments for research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nano Nuclear Energy's payments for research and development expense?
Nano Nuclear Energy (NNE) reported payments for research and development expense of $2.27M in Q3 2025.
What does payments for research and development expense mean?
Represents the cash outflows specifically directed toward the research and development of new technologies, products, or intellectual property. For early-stage companies, this metric serves as a primary indicator of the intensity of innovation and the pace of product development. It reflects the company's commitment to long-term growth through technological advancement.